RecruitingPhase 2NCT05248230
4D-710 in Adult Patients With Cystic Fibrosis
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- 4D Molecular Therapeutics
- Principal Investigator
- Sam Moskowitz MD4D Molecular Therapeutics
- Intervention
- 4D-710(biological)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2031
Study locations (20)
- University of Alabama Child Health Research Unit, Birmingham, Alabama, United States
- The University of Arizona, Tucson, Arizona, United States
- University of California San Francisco, San Francisco, California, United States
- National Jewish Health, Denver, Colorado, United States
- University of Florida, Gainesville, Florida, United States
- University of Miami Hospital, Miami, Florida, United States
- Northwestern Memorial Hospital, Chicago, Illinois, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Johns Hopkins Hospital, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
- Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Penn State Health, Hershey, Pennsylvania, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05248230 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.
- RECRUITINGPHASE1NCT07283770Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNCT07363304Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.Meyer Children's Hospital IRCCS